OhioHealth Riverside Methodist Hospital is now treating patients with peripheral artery disease (PAD) with the first drug-eluting stent to be used outside of the heart. Cook Medical’s Zilver PTX is a drug-coated stent that is used to reopen a long thigh artery, located above the knee (the femoropopliteal artery), narrowed or blocked due to PAD. This is the most common artery for PAD blockages.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60291-ohiohealth-riverside-hospital-zilver-ptx-drug-coated-stent-for-pad
Orbis, the international nonprofit that unites the world in the fight against blindness, is proud to land its new, state-of-the-art Flying Eye Hospital in Shenyang, China this week to commence its first training program, running from September 5 - 23. Six years in the making, the third-generation Flying Eye Hospital is the world’s only mobile ophthalmic teaching hospital on board an MD-10 aircraft, donated by FedEx. Hundreds of experts have come together to combine the latest in avionics, hospital engineering, technology and clinical expertise to make the new Flying Eye Hospital a reality. It features modular design, 3D technology and live broadcast capabilities, which enables Orbis and their expert Volunteer Faculty to train more doctors, nurses and healthcare professionals—ultimately treating more people and restoring their sight.
“Today, I am incredibly proud that our Flying Eye Hospital can get to work on its first program,” Bob Ranck, Orbis CEO and President, said. “It is a testament to the hundreds of volunteers, global corporate partners, governments and other individuals who have worked tirelessly to make this unique aircraft a reality, and we thank them one and all. Our mission at Orbis is to bring the world together to fight blindness, and the Flying Eye Hospital is an important tool for achieving this. It is an equal-parts teacher, envoy and advocate for the right to sight. We are excited to start this new chapter in Orbis history here in Shenyang, China.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7316251-orbis-flying-eye-hospital/
Going on the offensive against one of the most daunting challenges in cancer, The Leukemia & Lymphoma Society (LLS) today announced the launch of a groundbreaking, collaborative clinical trial for acute myeloid leukemia (AML), a deadly disease which has seen few improvements in treatments in more than 40 years.
Beat AML was announced yesterday by Vice President Biden, along with many new, Moonshot inspired initiatives across industry, non-profit and government.
AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more than 10,000 deaths each year. Despite advances in treating other blood cancers, the standard of treatment for AML – a combination of toxic chemotherapies – has remained the same for more than 40 years. Overall prognosis remains poor, with a five-year survival rate below 20 percent for patients over age 60.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554854-lls-beat-aml-acute-myeloid-leukemia/
Until recently, cancer patients looking for the most precise form of proton radiation therapy – “pencil-beam scanning” – had to narrow their search to about a half dozen centers in the United States that offer this treatment on a limited basis.
Today’s opening of the Scripps Proton Therapy Center in San Diego, Calif., marks the first time that a proton center in the United States is treating patients exclusively with this ultra-accurate technology, in every treatment room.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65691-scripps-proton-therapy-center-san-diego-precise-cancer-care
http://www.myweightlosssolutions.com
kettering weight loss solutions - kettering weight loss solutions - treating chronic conditio
Top Tips kettering weight loss solutions whipp road
for weight loss do they work :-) Appetite Suppressant - Garcinia Cambogia 1300 - Natural Fat Burner -2B 120Ct with alternate day fasting weight loss results
Also, learn about natural supplements that are sometimes recommended in alternative medicine for weight loss
OPTIFAST® as an Alternative to Weight Loss Surgery 20 Healthy Food Alternatives For Weight Loss
Looking for alternatives to weight loss surgery
Alternate day fasting weight loss calculator
Kettering weight loss solutions - transform your life.
You Should Know About It kettering weight loss solutions whipp road,Fat Burning Kitchen - REVIEW.
2018 - A new study found that you can use alternate day fasting to lose weight and still eat on your fast day alternate day fasting weight loss results.
Check out this alternate day fasting weight loss technique.
Before you do, here are some alternatives to weight loss surgery.
Food list; Healthy junk food recipes; Healthy food substitutes; Junk foods that are actually healthy; Healthy food alternatives for weight loss.
Risk factors, many individuals seeking effective weight loss programs find Cenegenics to be an attractive alternative to weight loss surgery.
2018 - Researchers develop pill alternative to weight loss surgery.
The tapping solution weight loss and body confidence.
Metabolic weight loss solutions reviews.
Beck diet solution weight loss workbook.
Medical weight loss solutions birmingham.
When a serious illness enters a family's life, there are many questions to ask and decisions to make. It is important to answer these questions quickly. The process can seem overwhelming. However, hospice care can be a wonderful resource for information about symptom management and comfort care. Hospice care professionals are available to help assess goals, pain management and care options during the decision-making process.
Are your symptoms minimal or moderate? Are these symptoms just starting to affect your life? If you want to continue treatment but also need comfort and symptom management, palliative care (often called comfort care) maybe an option. Palliative care is patient and family-centered care that optimizes quality of life by anticipating, preventing and treating suffering. Palliative care specialists address the physical, intellectual, emotional, social, and spiritual needs of patients and families, making sure they have access to all the information about the disease progression and the choices ahead. A patient can receive palliative care in conjunction with other treatments or therapies.
To view the multimedia release go to:
http://www.multivu.com/players/English/7429131-moments-of-life-by-hospice/
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
According to Congress’ “Don’t Let the Bed Bugs Bite” Act of 2009, bed bug populations have grown by 500 percent in the United States in recent years, primarily due to increased travel and antique merchandise. Bed bugs are creepy, crawly and hard to kill – an emotional topic that literally and figuratively keeps people up at night. Becoming educated on the bug, its habits, detecting, treating and preventing an infestation is an effective first step to control. Luckily, there is a solution: Ortho Home Defense Max BEDBUG Killer. Take back your bed and keep the critters from turning bedtime into bite time.
To view Multimedia News Release, go to http://www.multivu.com/players/English/47692-Ortho-Home-Defense-Max-BEDBUG-Killer/
The first comprehensive long-term study comparing different medications for type 2 diabetes is launching nationwide. The GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness) Study will compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64578-grade-glycemia-reduction-approaches-in-diabetes-comparative-effectiveness
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
An exclusive Grand Opening was held the evening of May 28th, 2016 in the newly opened FURSAN luxury Flagship Boutique, located on La Croisette18, Parcel 10, Porto Arabia, the Pearl Qatar; a magnificent, luxurious retail environment dedicated to opulence and consummate beauty.
FURSAN, based in Qatar, is the brainchild of Ibrahim Al-Haidos, Founder & Creative Director of the brand and the FURSAN Collection of unrivalled luxury handbags, designed in celebration of the tradition of Dazzah.
Asked what motivated him to design such exquisite, sumptuous handbags, Ibrahim Al-Haidos replied, “I have always had a romantic relationship with commerce and entrepreneurship. Combining my interest in leather goods and fashion, I seek to put Qatar on the luxury fashion map and make it a major destination for luxury brands. I want to give customers the true experience of extravagance by treating them as honored guests when they enter our glorious boutique.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7910551-fursan-grand-opening-flagship-boutique/
Nucletron, an Elekta company, and the world leader in brachytherapy, has launched Esteya®, a new approach for treating patients with skin cancer.
Over the last 30 years, more people were diagnosed with skin cancer worldwide than all other cancers combined, making it the most common type of cancer1. This represents a challenge for health care providers in the years to come. With a cure rate of more than 95 percent2, electronic brachytherapy offers a refined treatment modality with excellent cosmesis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62823-elekta-nucletron-esteya-electronic-brachytherapy-treating-skin-cancer